Gaudium IVF and Women Health Ltd has launched AI-powered Signature Labs and a new centre in South Extension, New Delhi, marking the first milestone in a planned 19-centre expansion. The initiative aims to standardise high-quality fertility care by combining AI-assisted embryology with globally benchmarked laboratory standards. The new facility, operational from July 16, 2026, integrates advanced reproductive medicine and the company's proprietary Signature Lab framework to enhance precision in embryo development.

The South Extension centre is the first step in the growth roadmap outlined during the company's Initial Public Offer. It features Gaudium IVF's AI-powered embryology ecosystem, including SiD (Sperm Identification Device) for advanced sperm assessment and ERICA (Embryo Ranking Intelligent Classification Assistant) for embryo evaluation. These technologies complement the expertise of embryologists with data-driven insights to improve consistency and confidence in IVF outcomes.

Details of the South Extension Centre

AI-Based Signature Labs and Expansion Plans

The Signature Lab model will be replicated across all new centres to ensure uniform standards of precision, safety and clinical excellence. Dr. Manika Khanna, Chairperson and Managing Director, stated that the launch reflects the company's commitment to making world-class fertility care accessible without compromising on standards. The expansion addresses growing demand for specialised fertility care driven by delayed parenthood and increased awareness of assisted reproductive technologies.

Gaudium IVF and Women Health Ltd has submitted a corrigendum to its audited annual results for the quarter and year ended March 31, 2026, to rectify inadvertent regrouping and typographical errors in comparative figures for the previous financial year. The company clarified that the errors were clerical in nature and related solely to the consolidated financial results for the year ended March 31, 2025, leaving the standalone results and the overall figures for the current year unchanged.

The Board of Directors approved the rectification at its meeting held on June 25, 2026, based on the recommendation of the Audit Committee. The statutory auditors, M/s. S K G N & Associates LLP, confirmed that the proposed changes are limited to the comparative figures of the previous year and do not necessitate any modification to the Independent Auditor's Report dated May 28, 2026. Consequently, the auditor's report remains valid and unchanged.

The corrections primarily involve adjustments in the Consolidated Balance Sheet and the Consolidated Statement of Profit and Loss. In the balance sheet, the regrouping affected the classification of Other Financial Assets and Other Current Assets within Current Assets, as well as the breakdown of Current Liabilities. Despite these shifts, the aggregate totals for Current Assets and Current Liabilities remained unchanged at ₹5,380.56 lakh and ₹3,801.08 lakh respectively for the year ended March 31, 2025.

In the Statement of Profit and Loss, the tax expense for the year ended March 31, 2025, was restated. The Current Tax was adjusted to ₹613.27 lakh from the previously reported ₹608.76 lakh, and Deferred Tax was revised to ₹11.61 lakh from ₹16.24 lakh. Consequently, the Total Tax Expense was corrected to ₹624.88 lakh, and the Profit for the year from continuing operations was restated to ₹1,917.86 lakh. The Total Comprehensive income for the year was adjusted to ₹1,931.13 lakh. The company noted that the correct Profit After Tax (PAT) figure of ₹1,913.13 lakh had already been reported in the financial results for the quarter ended December 31, 2025.

Corrections to Consolidated Balance Sheet

Corrections to Statement of Profit and Loss

The company emphasized that the rectification does not impact the Profit After Tax, Net Worth, or the overall financial position for the quarter and year ended March 31, 2026. The updated financial results, incorporating these changes, have been made available on the company's website.